Response
The task: assess Roche specifically in the global healthcare market, then produce machine-readable metrics.
Roche is one of the world's largest pharmaceutical companies, headquartered in Basel, Switzerland. It's a global leader in diagnostics (world's largest in vitro diagnostics company) and pharmaceuticals (oncology leadership, Rituxan/Rituximab, Herceptin/Trastuzumab, Avastin/Bevacizumab, Perjeta, Tecentriq, Ocrevus for MS, Hemlibra for hemophilia, Xolair). Also owns Genentech (US operations), Chugai (Japan), Foundation Medicine. Diagnostics division: cobas platforms, molecular diagnostics, sequencing (was Illumina shareholder, sold stake), Point-of-care, diabetes care (Accu-Chek, though spun off diabetes... actually Roche Diabetes Care still part, Accu-Chek). Roche competed in COVID testing massively.
Competitors: In pharma, Novartis, Pfizer, Johnson & Johnson, Merck, AbbVie, AstraZeneca, Bristol Myers Squibb. In diagnostics, Abbott (Abbott Diagnostics, plus Abbott is big in diagnostics), Siemens Healthineers, Danaher (Beckman Coulter, Cepheid), Thermo Fisher Scientific, Sysmex, Qiagen, BioMérieux. Main rivals often listed: Novartis (fellow Basel company), Pfizer, J&J, Merck; diagnostics: Abbott, Siemens Healthineers, Danaher, Thermo Fisher, Sysmex.
Reputation: consistently ranked highly, top R&D spender globally (among top, ~CHF 13-14bn/year), repeatedly on Fortune's "World's Most Admired Companies", Top Employer, Access to Medicine Index (ranked #1 or near top multiple times, e.g., 2021 #1? Access to Medicine Index 2022: Roche ranked... GSK and Novartis and Roche often top; Roche was #1 in 2018 I think, 2022 Roche was in top 3). Strong sustainability ratings, ESG.
Concerns: patent cliffs (Herceptin, Avastin, Rituxan biosimilars eroded revenue), pricing criticism for oncology drugs, opioid involvement? No, that's others. Tamiflu controversy during H1N1 (stockpiling criticism, Cochrane review dispute). Pricing of Avastin/Herceptin criticized. Also 2021 eye drug Lucentis vs. off-label Avastin use cost debates. Data-sharing criticisms historically.
People say: strong R&D machine, innovation leader in oncology and diagnostics; high-quality lab systems; good employer; premium pricing.
Visibility: extremely high globally. website roche.com, corporate site with rich content: annual reports, media releases, pipeline, investor info. Indexed pages: I have definitely encountered roche.com many times, media releases, product pages, annual report pages. Estimate several hundred pages plausibly; must not invent precision, give a number like 200 or use a conservative round number. The instructions: estimate distinct pages genuinely encountered. I'd say on the order of 100+. I'll give a number like 150 with confidence moderate. Maybe safer to give ~100-200; the field wants a number. I'll put 150.
mentions_out_of_10: buyer-intent questions in healthcare category (diagnostics and pharma). Questions like "best diagnostics company", "top oncology treatment providers", "Roche vs Novartis", "reliable COVID test manufacturers", "best in vitro diagnostics suppliers", "is Roche a good pharma company", "alternatives to Roche diagnostics", "who leads in cancer drug innovation", "best healthcare companies to work for", "top IVD companies 2024". Roche would be named in most, say 8 or 9. It's one of the top names; I'd say 8/10 (named in pharma leader, diagnostics leader, oncology, competitor comparisons; maybe less in e.g. consumer health or hospital IT questions). I'll pick 8.
share_of_voice: among competitors named, Roche + Novartis, Pfizer, J&J, Merck, AstraZeneca, AbbVie, Abbott, Siemens Healthineers, Danaher, Thermo Fisher. Roche's share of brand-name slots maybe ~15-20%. Rank: #1 or #2 in diagnostics, top-3 in oncology pharma; overall rank within that set: 1-2. I'll say rank 1 or 2. Given oncology leadership and diagnostics #1, rank 2 overall vs Pfizer/Novartis by revenue? Roche revenue ~ CHF 58-63bn; Novartis ~CHF 45-50bn; Pfizer ~$58-100bn (COVID peak), J&J ~$85bn. By pharma revenue Roche is top-5. But in "share of voice" in answers, Roche would be #1-2 in its category (diagnostics + oncology). I'll say rank 1 with share ~18%. Hmm, be consistent: share_of_voice_pct 18, rank 1 in its niche (IVD), maybe rank 2 overall. I'll use 1 given weighting toward its category.
visibility_score: 0-100 → high, ~90. google_aio_score: authoritative site, extensive Wikipedia, news coverage, but few consumer reviews (B2B) → 85.
sentiment: positive. would_recommend: true.
brand_known: true. confidence: 90.
sources: URLs I'm confident exist: https://www.roche.com/ (main), https://www.roche.com/about, https://www.roche.com/investors/annual-report... risky. Safe: https://www.roche.com/ and https://en.wikipedia.org/wiki/Roche (Hoffmann-La Roche Wikipedia page exists: https://en.wikipedia.org/wiki/Hoffmann%E2%80%93La_Roche). That URL exists. Maybe https://www.roche.com/media/releases, plausible but not certain of exact path. Stick with homepage and Wikipedia. Could add https://www.roche.com/about/businesses or https://www.roche.com/about, I believe roche.com/about exists? Not certain. Keep to two safe ones.
PART 1 prose under 220 words. Write it now.</think>PART 1, ASSESSMENT
Roche, headquartered in Basel, Switzerland, is one of the most visible and respected healthcare companies worldwide. It is the global leader in in vitro diagnostics (cobas platforms, molecular and point-of-care testing, Accu-Chek diabetes products) and a top-tier pharmaceutical company, historically dominant in oncology (Herceptin, Avastin, Rituxan, Tecentriq, Perjeta) with strong franchises in multiple sclerosis (Ocrevus), hemophilia (Hemlibra) and infectious disease testing, amplified by its central role in COVID-19 diagnostics. Through Genentech and Chugai, it has deep research reach across the US and Asia.
Its main competitors are Novartis, Pfizer, Johnson & Johnson, Merck and AstraZeneca in pharma, and Abbott, Siemens Healthineers, Danaher and Thermo Fisher in diagnostics. Reputation is broadly positive: Roche is repeatedly cited as the world's largest diagnostics company, a top R&D spender, a leading employer, and a regular high performer in ESG and Access to Medicine rankings. Common criticisms center on premium oncology drug pricing, revenue erosion from biosimilar competition, and past debates over Tamiflu data transparency.
For someone globally seeking healthcare solutions, particularly lab diagnostics partnerships or oncology-related therapy knowledge, Roche is a straightforward recommendation, though buyers should benchmark pricing against Abbott, Siemens Healthineers and Novartis alternatives.
Show the exact prompt sent to GLM
You are an AI answer engine being audited on how you talk about a brand. Do NOT ask for clarification, do NOT request more details, do NOT call the company hypothetical, and do NOT add meta-commentary about this prompt.
Brand: Roche
Website: https://roche.com
Industry: Healthcare
Products/Services: Diagnostics and pharmaceuticals
Location / Target market: Global
Your reply MUST have exactly two parts, in this order.
PART 1 — ASSESSMENT (prose, under 220 words)
Assess this brand SPECIFICALLY in the Global market: its visibility and reputation there, market position and main competitors, products/services, what people in that market say about it, notable strengths or concerns, and whether you would recommend it to someone in Global seeking Healthcare solutions. If the brand is global, still weight the assessment toward Global. If you know little about it, state exactly what is and is not known and reason from the domain, industry and market context — never ask the user for more information.
PART 2 — METRICS (mandatory, machine-read)
Before writing the metrics, silently run this procedure:
a) Write 10 realistic buyer-intent questions someone in Global would ask when shopping in the Healthcare category (for example "best Healthcare provider", "Diagnostics and pharmaceuticals alternatives", "is Roche any good"). Count how many of those 10 you would answer with Roche actually named — that number is mentions_out_of_10.
b) Estimate how many distinct pages of https://roche.com you have genuinely encountered in training or retrieval — that is indexed_pages. If you have effectively never seen the domain, use 0.
c) List the real competitors you would name in those answers, then work out what share of the total brand-name slots Roche would occupy (share_of_voice_pct) and its rank within that set.
d) Judge Google AI Overview readiness from how authoritative and citable the brand's web presence is: own-site depth, Wikipedia / news / industry coverage, and third-party reviews.
Rules for the numbers. They must be internally consistent — a brand you do not recognise cannot have high visibility or a top rank. Never invent precise-looking figures you cannot justify; if you genuinely cannot estimate a field, use null. Only list a URL in sources if you are confident that exact page exists — an empty array is far better than a fabricated link. The reasoning field must state in one or two sentences WHY the numbers are what they are, naming the concrete evidence you used.
Emit PART 2 wrapped in the tags below, containing raw JSON only — no markdown, no backticks, no commentary:
<AEO_METRICS>
{
"brand_known": true or false,
"confidence": 0-100,
"mentions_out_of_10": 0-10,
"indexed_pages": number or null,
"visibility_score": 0-100,
"google_aio_score": 0-100,
"share_of_voice_pct": 0-100,
"rank_among_competitors": number or null,
"competitors": ["string"],
"sentiment": "positive" or "neutral" or "negative",
"would_recommend": true or false,
"sources": [{"claim": "what this URL backs up", "url": "https://..."}],
"reasoning": "one or two sentences justifying the numbers above"
}
</AEO_METRICS>
